BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31078775)

  • 1. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    Muppa P; Parrilha Terra SBS; Sharma A; Mansfield AS; Aubry MC; Bhinge K; Asiedu MK; de Andrade M; Janaki N; Murphy SJ; Nasir A; Van Keulen V; Vasmatzis G; Wigle DA; Yang P; Yi ES; Peikert T; Kosari F
    J Thorac Oncol; 2019 Jul; 14(7):1286-1295. PubMed ID: 31078775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.
    Iams WT; Shiuan E; Meador CB; Roth M; Bordeaux J; Vaupel C; Boyd KL; Summitt IB; Wang LL; Schneider JT; Warner JL; Zhao Z; Lovly CM
    J Thorac Oncol; 2019 Nov; 14(11):1970-1981. PubMed ID: 31201935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
    Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
    Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
    Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
    Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment.
    Zhao X; Kallakury B; Chahine JJ; Hartmann D; Zhang Y; Chen Y; Zhang H; Zhang B; Wang C; Giaccone G
    J Thorac Oncol; 2019 May; 14(5):914-923. PubMed ID: 30735815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.
    Zhang Z; Wu P; Zhang C; Luo Y; Zhang G; Zeng Q; Wang L; Yang Z; Sun N; He J
    Front Immunol; 2021; 12():745769. PubMed ID: 34867972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
    Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
    Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune Characteristics of Small Cell Lung Cancer].
    Zhu Y; Wu S
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):889-896. PubMed ID: 33070515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
    Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
    J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Immune Infiltration and Prognostic Biomarkers in Small Cell Lung Cancer Based on Bioinformatic Methods from 3 Studies.
    Cao J; Yu C
    Comb Chem High Throughput Screen; 2023; 26(3):507-516. PubMed ID: 35400336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
    Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S
    Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
    Song Y; Sun Y; Sun T; Tang R
    Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer.
    Mony JT; Schuchert MJ
    Front Immunol; 2018; 9():2298. PubMed ID: 30374348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.